Workflow
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
IONSIonis Pharmaceuticals(IONS) ZACKS·2024-11-07 21:01

Ionis Pharmaceuticals (IONS) incurred a loss of 95 cents per share for third-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 1.16pershare.Earningsincludecompensationexpensesrelatedtoequityawards.Excludingthesespecialitems,adjustedlosspersharewas72centscomparedwithalossof85centspershareintheyear−agoquarter.Totalrevenueswere1.16 per share.Earnings include compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the year-ago quarter.Total revenues were 134 million in the third quarter, beating the Zacks Consensus Estimate of $129.0 million. Revenues declined 7% year ov ...